ELR510444

CAS : 1233948-35-0

Ref. 3D-IZB94835

Informations sur le produit

• Nom: ELR510444
• CAS: 1233948-35-0

Description

ELR510444 is a small molecule that inhibits the expression of survivin, an apoptosis protein. ELR510444 has potent antitumor activity and is currently being evaluated in clinical trials for the treatment of cervical cancer and renal cell cancer. This drug is being developed by Eli Lilly and Company. ELR510444 also has antiangiogenic properties, which may be due to its ability to inhibit tumor growth by blocking the growth factor VEGF signaling pathway. The mechanism of action of ELR510444 is still under investigation, but it has been shown to bind to the drug transporter ABCG2 and inhibit cellular proliferation in vitro.
ELR510444 was docked against a number of proteins implicated in cancer progression including EGFR, HER2, MET, PIK3CA, and AKT1 using molecular docking analysis. It was found that ELR510444 binds to these proteins with high affinity (Kd = 0.6-0.7 nM) and

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 368.47 g/mol
• Formule: C₁₉H₁₆N₂O₂S₂
• Degré de pureté: Min. 95%